| Document |
Document Title |
|
WO/2024/075756A1 |
Provided is a method for producing a library containing gene-modified cells. This library is useful in the functional evaluation of a specific region of a genome and the introduction, etc., of various types of mutations (such as SNPs) to...
|
|
WO/2024/076758A1 |
Methods and composition for growth and maintenance of Oct3/4+ SOX2+ NANOG+ pluripotent stem cells (PSCs) or generation and maintenance of CD7+ CD75+ CD77+ CD 130+ F11R+ naive PSCs in cell culture comprise the use of a small molecule-base...
|
|
WO/2024/075803A1 |
The present invention addresses the problem of providing: a method for testing a cranial nerve disease including schizophrenia, or a method for testing the sensitivity to a cranial nerve disease; and a reagent and a kit for use in the te...
|
|
WO/2024/075941A1 |
The present invention relates to super absorbent polymer-based surface fixation technology for extracellular vesicles or cells and, more specifically, to a technology and applications thereof, the technology fixing, to the surface of a s...
|
|
WO/2024/077158A1 |
In various aspects and embodiments, the present disclosure provides methods for generating T cell populations for cell therapy, including T lymphocytes (T cells) and progenitor T cells. In various embodiments, the invention provides for ...
|
|
WO/2024/076173A1 |
Disclosed are a composition for inducing differentiation of adipose-derived stem cells into dermal papilla cells, and a differentiation method using the composition. The composition for inducing differentiation and the differentiation me...
|
|
WO/2024/077255A1 |
Transgenic bioincubators are provided having an FAH transgene or endogenous FAH modified with an inducible promoter. The inducible promoter allows for control of the expression of FAH in the presence or absence of an inducer, for purpose...
|
|
WO/2024/076329A1 |
The invention relates to an exosome-based biocompatible implant obtained by spraying exosomes obtained from stem cells onto implant materials consisting of different materials. Said exosomes are attached to the implant material at a leve...
|
|
WO/2024/076507A1 |
Methods for improving parthenogenesis efficiency by DWT1 and BABY BOOM transcription factors in plants are provided. A rice embryo trigger transcription factor BABY BOOM1 can initiate embryogenesis when expressed in the unfertilized egg ...
|
|
WO/2024/076182A1 |
The present invention relates to a medium composition for preparing a salivary gland organoid. Also, the present invention relates to: a method for preparing a salivary gland organoid, comprising a step of culturing salivary gland-derive...
|
|
WO/2024/074376A1 |
The present invention relates to a macrophage, genetically engineered to overexpress Interleukin-10 (IL-10) or IL-10 in combination with Matrix Metallopeptidase 9 (MMP9). Such a macrophage may be for use in treatment of an inflammatory c...
|
|
WO/2024/077159A1 |
The present disclosure provides for efficient ex vivo processes for generating B cell lineages from human induced pluripotent stem cells (iPSCs). Cells generated according to the disclosure in various embodiments are functional and/or mo...
|
|
WO/2024/075675A1 |
The present invention relates to: a stem cell population derived from human milk tooth dental pulp, the stem cell population being characterized in that at least 90% of the stem cell population is CD117-negative, CD73-positive, CD90-posi...
|
|
WO/2024/071109A1 |
The purpose of the present invention is to simplify a cell culture device. The present invention relates to a cell culture device (100) for culturing cells, the cell culture device being equipped with: a culture tank (1) for pooling a cu...
|
|
WO/2024/066919A1 |
Disclosed herein are a method for differentiating a stem cell into a caudal serotonergic neuron, a complete culture medium, and use thereof. Specifically, a small molecule compound is added to form a new culture medium, so that human plu...
|
|
WO/2024/071923A1 |
According to an aspect of the technology disclosed in the present application, the present invention relates to a cell line in which exosomes loaded with FAF1 protein are stably expressed, and relates to: a cell line, which can produce, ...
|
|
WO/2024/067888A1 |
Provided is a varicella zoster vaccine. Specifically, the vaccine comprises an immune composition, and the immune composition comprises an antigen component and a granulin component. The granulin component comprises a nanogranulin protei...
|
|
WO/2024/068760A1 |
This invention relates to methods of making immunoresponsive cells, immunoresponsive cells thereof, pharmaceutical compositions, kits, uses thereof and methods of treatment. In particular, there is provided a method of making an immunore...
|
|
WO/2024/071918A1 |
The present invention relates to a composition for manufacturing a cell film, containing a solution of acrylamide, bis-acrylamide, sodium acrylate, and TEMED in distilled water, a method for manufacturing a cell film, a cell film, and a ...
|
|
WO/2024/070382A1 |
The present invention provides: novel fine particles that include miRNA associated with NK cell activation and that are derived from a culture supernatant of stem cells derived from dental pulp or a culture supernatant of stem cells deri...
|
|
WO/2024/067389A1 |
The present application belongs to the technical field of biomedicine. More specifically, the present application relates to a kit for detecting whether a subject suffers from multiple sclerosis (MS). Furthermore, the present application...
|
|
WO/2024/071039A1 |
The present disclosure provides a pharmaceutical composition for treating or preventing T cell-related disorders, the pharmaceutical composition containing induced regulatory T cells having high functionality and a stable immunosuppressi...
|
|
WO/2024/068648A1 |
Provided herein is a cell culture serum free medium for culturing cells in-vitro, and methods of using the cell culture serum free medium.
|
|
WO/2024/066026A1 |
Provided is a chimeric antigen receptor targeting IL13Rα2, comprising: (1) an optimized anti-IL13Rα2 scFv sequence; (2) an optimized hinge region/spacer region; (3) a transmembrane region (TM); (4) a CD28 costimulatory domain and a 4-1...
|
|
WO/2024/065892A1 |
Provided is use of a reagent for detecting an eosinophil, an eosinophil and a cytoplasm content thereof, and a lipid metabolite hydroxy docosahexaenoic acid, which belongs to the technical field of medical treatment and medicines. Provid...
|
|
WO/2024/072157A1 |
The present invention relates to a novel method for preparing an organoid, that addresses the issue of low organoid generation rate by enzymatic treatment by replacing the enzymatic cell dissociation for organoid preparation in the conve...
|
|
WO/2024/068898A1 |
The present invention provides pre-mRNA trans-splicing molecules (RTMs) that are useful for correcting mutations in the OPA1 gene. Also provided are methods of using the RTMs as gene therapy (e.g., ex vivo and in vivo gene therapy) for t...
|
|
WO/2024/071374A1 |
The present invention addresses the problem of providing: a cell screening method that has excellent screening sensitivity and screening efficiency; a nucleic acid production method for acquiring nucleic acid from cells obtained by the s...
|
|
WO/2024/071397A1 |
The present invention provides an IL13RA2-targeting herpes simplex virus in which an anti-IL13RA2 antibody or an antigen-binding fragment thereof is presented on the viral surface. Also provided is an anti-IL13RA2 antibody or an antigen-...
|
|
WO/2024/072998A1 |
The disclosure relates to adoptive cell therapy compositions including a population of isolated immune cells that are obtained from a donor subject. The immune cells can be modified to suppress Bruton's tyrosine kinase (BTK), interleukin...
|
|
WO/2024/072316A1 |
The present disclosure relates to methods of generating induced pluripotent stem cell (iPSC)-derived Kupffer cells (iKCs), where the method comprises contacting iPSC-derived macrophages with iPSC-derived hepatocytes (iHeps), kits for gen...
|
|
WO/2024/072444A1 |
This disclosure describes methods for growing cells in a controlled environment in a growing room, transporting the cells to a harvest room, and removing the cells from the controlled environment in the harvest room. The disclosed method...
|
|
WO/2024/065297A1 |
Embodiments of the present invention provide a chimeric antigen receptor with a light chain variable region having a sequence set forth in SEQ ID NO: 1 and a heavy chain variable region having a sequence set forth in SEQ ID NO: 2. The ch...
|
|
WO/2024/071336A1 |
The present invention relates to a bacterial exopolysaccharide having a repeating structure comprising a series of repeating units represented by formula (I), and to the use of the bacterial exopolysaccharide for immunopotentiation. (In ...
|
|
WO/2024/067759A1 |
The present invention relates to a novel humanized anti-human CLDN18.2 antibody and an antigen-binding fragment thereof. The present invention also relates to a preparation method for the antibody. The present invention further relates t...
|
|
WO/2024/068934A1 |
The present invention provides an otic neural progenitor (ONP) cell culture substrates comprising a protein matrix composed of laminin (211), laminin (521) and laminin (111), where the amounts of laminin (211), the laminin (521) and the ...
|
|
WO/2024/073751A1 |
Provided herein are compositions and methods of making genetically engineered cells having a plurality of modifications (e.g., insertions or deletions), cells and cell populations produced by the methods described herein, and methods inv...
|
|
WO/2024/067821A1 |
Provided is a modified cell, wherein the modified cell is formed by binding a complex protein to a cell surface marker molecule of the modified cell. The complex protein comprises a part specifically binding to the cell surface marker mo...
|
|
WO/2024/073570A1 |
Provided are materials and methods for rejuvenating senescent cells. Senescent cells are transduced with a viral vector to express Oct4, Sox2, and Klf4 proteins for partial cell reprogramming and a dominant negative NFκBIA protein to su...
|
|
WO/2024/065268A1 |
Provided is a single-domain antibody or antigen-binding fragment capable of identifying ANG-2, and a multispecific antibody. The antibody or antigen-binding fragment has a heavy chain variable region as represented by any one of SEQ ID N...
|
|
WO/2024/067682A1 |
The present application relates to a genetically modified immune cell for expressing a recombinant human CD16 protein. The recombinant human CD16 protein has additions, deletions and replacements of, or any combination of the additions, ...
|
|
WO/2024/067673A1 |
The present application provides identification, in vitro amplification, and an application method of memory CD8 T cells specific for an antigen in a solid tumor-draining lymph node.
|
|
WO/2024/067770A1 |
Provided is a lentivirus packaging titer kit. An existing virus packaging vector is modified to construct a high-virus packaging titer kit. For conventional virus helper plasmids, a replication origin, a promoter, a terminator, an enhanc...
|
|
WO/2024/068960A1 |
The present invention relates to the method for producing a three-dimensional (3D) model of multiple myeloma (MM), in the form of spheroids, by co-culturing stem cells/mesenchymal stromal cells, endothelial progenitors and primary plasma...
|
|
WO/2024/066416A1 |
Provided are a CXCL-BPI fusion protein capable of being used for treating gram-negative bacterial infections, an encoding nucleic acid thereof, an expression and preparation method therefor, and use thereof for preparing a pharmaceutical...
|
|
WO/2024/072820A1 |
In alternative embodiments, provided are compositions, including compositions, products of manufacture and kits, and methods, for manipulating, and in particular, augmenting or increasing, T cell activity in vitro and in vivo, by for exa...
|
|
WO/2024/066080A1 |
An arsenic compound-based tumor vaccine, a preparation method therefor, and an application thereof. The arsenic compound-based tumor vaccine comprises tumor cells treated by an arsenic compound, may activate an anti-tumor immune response...
|
|
WO/2024/071223A1 |
The present invention provides a method for producing an angiogenesis-inducing cell population. This method comprises: (1) a step for coculturing a cell population derived from bone marrow fluid or blood with OP9 cells; or (2) a step for...
|
|
WO/2024/067227A1 |
Provided are an engineered mesenchymal stem cell (MSC), a pharmaceutical composition comprising same, and use thereof in the preparation of a medicament for treating cancer. The mesenchymal stem cell (MSC) comprises an introduced NQO1 pr...
|
|
WO/2024/066156A1 |
The present invention provides a method for preparing a mesenchymal stem cell (MSC), a mesenchymal stem cell, and use thereof. According to the method, a trophoblast stem cell (TSC) is obtained by means of inducing EPSC differentiation, ...
|
